J
Johnny Mahlangu
Researcher at University of the Witwatersrand
Publications - 168
Citations - 7881
Johnny Mahlangu is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Haemophilia & Medicine. The author has an hindex of 31, co-authored 139 publications receiving 5619 citations. Previous affiliations of Johnny Mahlangu include National Health Laboratory Service.
Papers
More filters
Journal ArticleDOI
Guidelines for the management of hemophilia.
A. Srivastava,A. K. Brewer,Evelien P. Mauser-Bunschoten,Nigel S. Key,Steve Kitchen,Adolfo Llinás,C. A. Ludlam,Johnny Mahlangu,K. Mulder,M.-C. Poon,Alison Street +10 more
TL;DR: These evidence‐based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion‐transmitted infections.
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg,Johnny Mahlangu,Benjamin Kim,Christophe Schmitt,Michael U. Callaghan,Guy Young,Elena Santagostino,Rebecca Kruse-Jarres,Claude Negrier,Craig M. Kessler,Nancy Valente,Elina Asikanius,Gallia G. Levy,Jerzy Windyga,Midori Shima +14 more
TL;DR: Empicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no proPHylaxis among participants with hemophilia A with inhibitors and resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing‐agent prophylum.
Journal ArticleDOI
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Johnny Mahlangu,Johannes Oldenburg,Ido Paz-Priel,Claude Negrier,Markus Niggli,M Elisa Mancuso,M Elisa Mancuso,Christophe Schmitt,Víctor Jiménez-Yuste,Christine L. Kempton,Christophe Dhalluin,Michael U. Callaghan,Willem Bujan,Midori Shima,Joanne I. Adamkewicz,Elina Asikanius,Gallia G. Levy,Rebecca Kruse-Jarres +17 more
TL;DR: Empicizumab prophylaxis administered subcutaneously once weekly or every 2 weeks led to a significantly lower bleeding rate than no proPHylaxis among persons with hemophilia A without inhibitors; more than half of the participants who received prophYLaxis had no treated bleeding events.
Journal ArticleDOI
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu,Jerry S. Powell,Margaret V. Ragni,Pratima Chowdary,Neil C. Josephson,Ingrid Pabinger,H. Hanabusa,Naresh Gupta,Roshni Kulkarni,Patrick F. Fogarty,David J. Perry,Amy D. Shapiro,K. John Pasi,Shashikant Apte,Ivan Nestorov,Haiyan Jiang,Shuanglian Li,Srividya Neelakantan,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Nigel Dodd,Karen Nugent,Gloria Vigliani,Alvin Luk,Aoife Brennan,Glenn F. Pierce +27 more
TL;DR: In this paper, the authors evaluated the safety, efficacy, and pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥12 years with severe hemophilia A.